(AOF) – Transgene and NEC Corporation, a specialist in information technology, networks and artificial intelligence (AI), announced the first positive data from TG4050, an individualized therapeutic vaccine targeting tumor mutations specific to each patient (neoantigens). These data demonstrate the immunogenicity of the vaccine as well as the first signs of clinical activity.
They were generated in two multicenter Phase I trials in patients with ovarian cancer and head and neck cancer. Co-developed by the two partners, TG4050 is the first candidate from Transgene’s myvac platform and benefits from NEC’s cutting-edge AI capabilities.
In the ovarian cancer trial, in a patient treated with TG4050 after elevation of CA-125 level, normalization of this marker was observed, as well as no clinical progression for 9 months, up to ” on the death of the patient due to an unrelated chronic disease. Another patient with radiological lesions is stable and still on treatment with TG4050, 9 months after the first injection.
In the early treatment arm of the head and neck trial, both patients have been treated with TG4050 for 10 and 5 months respectively and are stable. They continue to receive their treatment.
To date, the vaccine has been well tolerated and no serious side effects were reported in the two studies. The undesirable effects are in accordance with the observations previously made with the MVA viral vector. They consist mainly of mild, transient symptoms, mainly reactions at the injection site.
Additional data will be generated in the coming months. Transgene plans to present them at a major oncology congress in 2022.
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights owned by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial or non-commercial exploitation, creation of hypertext link or reuse in any way whatsoever of this information is subject to the prior written agreement of OPTION. FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from sources it considers the most reliable. However, subject to gross negligence, OPTION FINANCES SAS and its contributors in no way guarantee the absence of errors and defects, even hidden, nor the exhaustiveness or lack of conformity for any use whatsoever of these data and of OPTION FINANCE. SAS or one of its contributors, and cannot be held responsible for delays or interruptions that could affect access to them. The user of the OPTION FINANCE SAS service will use AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.
Receive our latest news
Every morning, the information to remember about financial markets.